Monthly incidence and conditional probability of irAEs
| Landmark month | Patients alive on landmark day with no prior irAE, N | Patients with irAEs in next 30 days, n (%) | Patients with irAEs at any time in the future, n (%) | 95% CI for future irAE at any time |
| 0 | 470 | 47 (10.0) | 186 (39.6) | 35.1 to 44.2 |
| 1 | 415 | 28 (6.8) | 139 (33.5) | 29.0 to 38.3 |
| 2 | 358 | 25 (7.0) | 111 (31.0) | 26.3 to 36.1 |
| 3 | 312 | 13 (4.2) | 86 (27.6) | 22.7 to 32.9 |
| 4 | 270 | 19 (7.0) | 73 (27.0) | 21.8 to 32.8 |
| 5 | 222 | 11 (5.0) | 54 (24.3) | 18.8 to 30.5 |
| 6 | 193 | 11 (5.7) | 43 (22.3) | 16.6 to 28.8 |
| 7 | 176 | 5 (2.8) | 32 (18.2) | 12.8 to 24.7 |
| 8 | 163 | 6 (3.7) | 27 (16.6) | 11.2 to 23.2 |
| 9 | 146 | 2 (1.4) | 21 (14.4) | 9.1 to 21.1 |
| 10 | 132 | 2 (1.5) | 19 (14.4) | 8.9 to 21.6 |
| 11 | 118 | 0 (0.0) | 17 (14.4) | 8.6 to 22.1 |
| 12 | 109 | 3 (2.8) | 17 (15.6) | 9.4 to 23.8 |
CI, cumulative incidence; irAEs, immune-related adverse events.